HippoFi and its subsidiary PUR Biologics have FDA 510(k) clearance for ActiveOrb technology and a global license from Zimmer Biomet to use in the spine market, according to a Sept. 7 news release. The companies are working under a joint commercialization research agreement to produce spine-specific products.
The synthetic biomaterial is expected to launch in 2024.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
